RU2010116271A - Ангиогенные клетки из плацентарного перфузата человека - Google Patents
Ангиогенные клетки из плацентарного перфузата человека Download PDFInfo
- Publication number
- RU2010116271A RU2010116271A RU2010116271/10A RU2010116271A RU2010116271A RU 2010116271 A RU2010116271 A RU 2010116271A RU 2010116271/10 A RU2010116271/10 A RU 2010116271/10A RU 2010116271 A RU2010116271 A RU 2010116271A RU 2010116271 A RU2010116271 A RU 2010116271A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- isolated
- placental
- placental perfusate
- population
- Prior art date
Links
- 230000003169 placental effect Effects 0.000 title claims abstract 28
- 230000002491 angiogenic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 40
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract 34
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract 34
- 210000004700 fetal blood Anatomy 0.000 claims abstract 8
- 230000010412 perfusion Effects 0.000 claims abstract 7
- 210000002826 placenta Anatomy 0.000 claims abstract 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract 5
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract 5
- 108091008605 VEGF receptors Proteins 0.000 claims abstract 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract 5
- 210000004369 blood Anatomy 0.000 claims abstract 3
- 239000008280 blood Substances 0.000 claims abstract 3
- 210000001185 bone marrow Anatomy 0.000 claims abstract 3
- 239000011159 matrix material Substances 0.000 claims abstract 3
- 210000005259 peripheral blood Anatomy 0.000 claims abstract 3
- 239000011886 peripheral blood Substances 0.000 claims abstract 3
- 102000005741 Metalloproteases Human genes 0.000 claims abstract 2
- 108010006035 Metalloproteases Proteins 0.000 claims abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 238000000338 in vitro Methods 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000014888 Vascular hypertensive disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Способ формирования сосудов из популяции клеток плацентарного перфузата, включающий приведение в контакт указанной популяции клеток в условиях, которые способствуют формированию сосудов. ! 2. Способ по п.1, где указанная популяция клеток плацентарного перфузата представляет собой все нуклеарные клетки плацентарного перфузата. ! 3. Способ по п.1, где указанное приведение в контакт включает приведение в контакт указанных клеток с VEGF (50-200 нг/мл), TGF-β (1-5 нг/мл), FGF (10-50 нг/мл), а также одной или нескольких матриксных металлопротеаз (1-3 единицы/мл каждая). ! 4. Способ по п.1, где указанное приведение в контакт осуществляют in vitro. ! 5. Способ по п.1, где указанное приведение в контакт осуществляют in vivo. ! 6. Способ по п.1, где указанная популяция клеток плацентарного перфузата включает клетки плацентарного перфузата, выделенные при перфузии одной плаценты. ! 7. Способ по п.6, где указанные клетки плацентарного перфузата представляют собой клетки CD34+. ! 8. Способ по п.7, где указанные клетки CD34+ представляют собой клетки CD34+CD45-. ! 9. Способ по п.6 или 7, где указанные клетки CD34+ или клетки CD34+CD45- экспрессируют более высокий уровень по меньшей мере одного из CD31, CXCR4 или VEGFR по сравнению с эквивалентным числом клеток CD34+ пуповинной крови. ! 10. Способ по п.1, где указанная популяция клеток плацентарного перфузата включает выделенные клетки CD34+, выделенные не из указанного перфузата. ! 11. Способ по п.10, где указанные клетки CD34+ выделяют из плаценты. ! 12. Способ по п.10, где указанные клетки CD34+ выделяют из пуповинной крови, плацентарной крови, периферической крови или костного мозга. ! 13. Способ по п.10, где указанные клетки CD34+ экспрессируют более высокий ур�
Claims (27)
1. Способ формирования сосудов из популяции клеток плацентарного перфузата, включающий приведение в контакт указанной популяции клеток в условиях, которые способствуют формированию сосудов.
2. Способ по п.1, где указанная популяция клеток плацентарного перфузата представляет собой все нуклеарные клетки плацентарного перфузата.
3. Способ по п.1, где указанное приведение в контакт включает приведение в контакт указанных клеток с VEGF (50-200 нг/мл), TGF-β (1-5 нг/мл), FGF (10-50 нг/мл), а также одной или нескольких матриксных металлопротеаз (1-3 единицы/мл каждая).
4. Способ по п.1, где указанное приведение в контакт осуществляют in vitro.
5. Способ по п.1, где указанное приведение в контакт осуществляют in vivo.
6. Способ по п.1, где указанная популяция клеток плацентарного перфузата включает клетки плацентарного перфузата, выделенные при перфузии одной плаценты.
7. Способ по п.6, где указанные клетки плацентарного перфузата представляют собой клетки CD34+.
8. Способ по п.7, где указанные клетки CD34+ представляют собой клетки CD34+CD45-.
9. Способ по п.6 или 7, где указанные клетки CD34+ или клетки CD34+CD45- экспрессируют более высокий уровень по меньшей мере одного из CD31, CXCR4 или VEGFR по сравнению с эквивалентным числом клеток CD34+ пуповинной крови.
10. Способ по п.1, где указанная популяция клеток плацентарного перфузата включает выделенные клетки CD34+, выделенные не из указанного перфузата.
11. Способ по п.10, где указанные клетки CD34+ выделяют из плаценты.
12. Способ по п.10, где указанные клетки CD34+ выделяют из пуповинной крови, плацентарной крови, периферической крови или костного мозга.
13. Способ по п.10, где указанные клетки CD34+ экспрессируют более высокий уровень CD31, CXCR4 или VEGFR по сравнению с эквивалентным числом клеток CD34+ пуповинной крови.
14. Способ по п.10, где указанные клетки CD34+ представляют собой клетки CD34+CD45-.
15. Способ лечения индивидуума, страдающего сердечным или сосудистым заболеванием, нарушением, патологическим состоянием или недостаточностью, включающий введение плацентарного перфузата человека или клеток плацентарного перфузата человека указанному индивидууму в количестве, достаточном для лечения указанного заболевания, нарушения, патологического состояния или недостаточности.
16. Способ по п.15, где указанное заболевание, нарушение, патологическое состояние или недостаточность представляет собой заболевание периферических сосудов, острый или хронический инфаркт миокарда, кардиомиопатию, застойную или хроническую сердечную недостаточность, сердечно-сосудистую ишемию, легочное сосудистое гипертензивное заболевание, заболевание периферических артерий или ревматический порок сердца.
17. Способ по п.15, где указанные клетки плацентарного перфузата представляют собой все нуклеарные клетки плацентарного перфузата.
18. Способ по п.15, где указанная популяция клеток плацентарного перфузата включает клетки плацентарного перфузата, выделенные при перфузии одной плаценты.
19. Способ по п.18, где указанные клетки плацентарного перфузата представляют собой клетки CD34+.
20. Способ по п.19, где указанные клетки CD34+ представляют собой клетки CD34+CD45-.
21. Способ по п.19 или 20, где указанные клетки CD34+ или клетки CD34+CD45- экспрессируют более высокий уровень по меньшей мере одного из CD31, CXCR4 или VEGFR по сравнению с эквивалентным числом клеток CD34+ пуповинной крови.
22. Способ по п.15, где указанная популяция клеток плацентарного перфузата включает выделенные клетки CD34+, выделенные не из указанного перфузата.
23. Способ по п.22, где указанные клетки CD34+ выделяют из плаценты.
24. Способ по п.22, где указанные клетки CD34+ выделяют из пуповинной крови, плацентарной крови, периферической крови или костного мозга.
25. Способ по п.22, где указанные клетки CD34+ экспрессируют более высокий уровень CD31, CXCR4 или VEGFR по сравнению с эквивалентным числом клеток CD34+ пуповинной крови.
26. Способ по п.15, где указанные клетки плацентарного перфузата вводят на клеточном каркасе или матрице.
27. Способ по п.15, где указанные клетки плацентарного перфузата вводят внутривенно.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99567907P | 2007-09-26 | 2007-09-26 | |
| US60/995,679 | 2007-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010116271A true RU2010116271A (ru) | 2011-11-10 |
Family
ID=40043062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010116271/10A RU2010116271A (ru) | 2007-09-26 | 2008-09-26 | Ангиогенные клетки из плацентарного перфузата человека |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090104164A1 (ru) |
| EP (1) | EP2205719A1 (ru) |
| JP (6) | JP5703493B2 (ru) |
| KR (9) | KR20210118946A (ru) |
| CN (1) | CN101978045A (ru) |
| AU (1) | AU2008305516A1 (ru) |
| BR (1) | BRPI0818191A8 (ru) |
| CA (1) | CA2700613C (ru) |
| IL (4) | IL204762A0 (ru) |
| MX (1) | MX2010003217A (ru) |
| RU (1) | RU2010116271A (ru) |
| WO (1) | WO2009042201A1 (ru) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| EP2206772A3 (en) | 2000-12-06 | 2010-08-04 | Robert J. Hariri | Method of collecting placental stem cells |
| US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
| ES2559031T3 (es) * | 2001-02-14 | 2016-02-10 | Anthrogenesis Corporation | Renovación y repoblación de tejidos descelularizados y órganos cadavéricos por células madre |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| WO2004047770A2 (en) * | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| GB0321337D0 (en) * | 2003-09-11 | 2003-10-15 | Massone Mobile Advertising Sys | Method and system for distributing advertisements |
| JP2007531116A (ja) * | 2004-03-26 | 2007-11-01 | セルジーン・コーポレーション | 幹細胞バンクを提供するためのシステム及び方法 |
| AU2006304277B2 (en) | 2005-10-13 | 2012-07-05 | Celularity Inc. | Immunomodulation using placental stem cells |
| CN101326281A (zh) * | 2005-10-13 | 2008-12-17 | 人类起源公司 | 用源自胎盘的干细胞制备少突胶质细胞 |
| ES2671355T3 (es) | 2005-12-29 | 2018-06-06 | Anthrogenesis Corporation | Poblaciones de células madre placentarias |
| EP1976978A2 (en) * | 2005-12-29 | 2008-10-08 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| NZ595854A (en) * | 2006-10-23 | 2013-04-26 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations (ELOVL2, ST3GAL6, STGALNAC5, SLC12A8) |
| CA2677679A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
| EP3763376A1 (en) | 2007-02-12 | 2021-01-13 | Celularity, Inc. | Treatment of inflammatory diseases using placental stem cells |
| US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
| KR20210118946A (ko) * | 2007-09-26 | 2021-10-01 | 안트로제네시스 코포레이션 | 인간 태반 관류액으로부터의 혈관형성 세포 |
| NZ617412A (en) | 2007-09-28 | 2015-06-26 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| KR20220025141A (ko) | 2008-08-20 | 2022-03-03 | 셀룰래리티 인코포레이티드 | 개선된 세포 조성물 및 그의 제조 방법 |
| KR20180108887A (ko) * | 2008-08-20 | 2018-10-04 | 안트로제네시스 코포레이션 | 단리된 태반 세포를 사용한 뇌졸중 치료 |
| WO2010021756A1 (en) | 2008-08-22 | 2010-02-25 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| JP5869342B2 (ja) | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
| WO2011002959A1 (en) * | 2009-07-02 | 2011-01-06 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
| US9163212B2 (en) * | 2010-01-25 | 2015-10-20 | Warsaw Orthopedic, Inc. | Osteogenic cell delivery matrix |
| EP2529007B1 (en) | 2010-01-26 | 2017-07-12 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
| EP3351625A1 (en) | 2010-02-18 | 2018-07-25 | Osiris Therapeutics, Inc. | Methods of manufacture of immunocompatible amniotic membrane products |
| KR101993254B1 (ko) | 2010-04-07 | 2019-06-26 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 혈관신생 |
| JP2013523823A (ja) | 2010-04-08 | 2013-06-17 | アントフロゲネシス コーポレーション | 胎盤幹細胞を用いるサルコイドーシスの治療 |
| US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
| KR20190108599A (ko) | 2010-07-13 | 2019-09-24 | 안트로제네시스 코포레이션 | 천연 킬러 세포의 생성 방법 |
| RU2435594C1 (ru) * | 2010-10-04 | 2011-12-10 | Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи | Способ лечения плацентарной недостаточности во ii-iii триместрах беременности |
| AR093183A1 (es) | 2010-12-31 | 2015-05-27 | Anthrogenesis Corp | Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras |
| TWI602570B (zh) | 2011-06-01 | 2017-10-21 | 安瑟吉納西斯公司 | 使用胎盤幹細胞之疼痛治療 |
| US9925221B2 (en) | 2011-09-09 | 2018-03-27 | Celularity, Inc. | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
| JP6571537B2 (ja) * | 2013-03-13 | 2019-09-04 | ザ ユニバーシティー オブ クイーンズランド | 療法および予防のための細胞を単離する方法 |
| WO2014152177A1 (en) | 2013-03-15 | 2014-09-25 | Anthrogenesis Corporation | Modified t lymphocytes |
| WO2014165602A1 (en) | 2013-04-02 | 2014-10-09 | University Of Florida Research Foundation, Inc. | Compositions and methods for induction and modulation of angiogenesis and methods and assays for identifying angiogenesis modulators |
| EP3068432A4 (en) * | 2013-11-15 | 2017-04-19 | Anthrogenesis Corporation | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
| CN103756965B (zh) * | 2014-01-27 | 2016-04-06 | 山东省齐鲁干细胞工程有限公司 | 一种从胎盘中灌洗造血干细胞的方法 |
| CN104152405B (zh) * | 2014-08-15 | 2016-06-29 | 博雅干细胞科技有限公司 | 从胎盘中分离提取造血干细胞的方法 |
| CA3177726A1 (en) | 2015-05-21 | 2016-11-24 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
| WO2017014561A1 (ko) * | 2015-07-20 | 2017-01-26 | 가톨릭대학교 산학협력단 | 제대혈 ｃｄ３４ 양성 세포에서 골수유래억제세포로의 분화 유도 및 증식 방법, 및 상기 골수유래억제세포의 용도 |
| KR20170020273A (ko) * | 2015-08-12 | 2017-02-22 | (주)차바이오텍 | 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도 |
| US20190314424A1 (en) * | 2016-12-05 | 2019-10-17 | Celularity, Inc. | Treatment of lymphedema and related conditions using placental adherent cells |
| CN107058224B (zh) * | 2017-02-10 | 2020-08-21 | 广东唯泰生物科技有限公司 | 一种以胎盘为来源的造血干细胞提取及冻存方法 |
| CN113454207A (zh) | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 |
| CN109652372A (zh) * | 2019-01-09 | 2019-04-19 | 陕西九州细胞基因工程有限公司 | 一种人胎盘组织源造血干细胞的快速分离、制备方法 |
| JP6977969B2 (ja) * | 2019-03-22 | 2021-12-08 | 株式会社ガイアバイオメディシン | 免疫細胞提供システム |
| WO2020252464A1 (en) | 2019-06-14 | 2020-12-17 | Celularity Inc. | Populations of natural killer cells for treating cancers |
| WO2021016621A1 (en) | 2019-07-25 | 2021-01-28 | Celularity Inc. | Populations of natural killer cells comprising a cd38 chimeric antigen receptor |
| WO2021022229A1 (en) | 2019-07-31 | 2021-02-04 | Celularity Inc. | Populations of natural killer cells comprising a cleavage resistant cd16 |
| WO2021113849A1 (en) | 2019-12-05 | 2021-06-10 | Celularity Inc. | Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16 |
| US20220000919A1 (en) | 2020-01-29 | 2022-01-06 | Celularity Inc. | Placental derived natural killer cells for treatment of coronavirus infections |
| WO2023278628A1 (en) | 2021-06-29 | 2023-01-05 | Celularity Inc. | Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml |
| CR20240104A (es) | 2021-07-29 | 2024-06-28 | Celularity Inc | Células NK derivadas de la placenta como senolítico para usos terapéuticos y otros. |
| AU2023206330A1 (en) | 2022-01-11 | 2024-08-22 | Celularity Inc. | Cleavage resistant cd16 constructs and uses thereof |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862002A (en) * | 1962-05-08 | 1975-01-21 | Sanfar Lab Inc | Production of physiologically active placental substances |
| US5863531A (en) * | 1986-04-18 | 1999-01-26 | Advanced Tissue Sciences, Inc. | In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework |
| US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| US5605822A (en) * | 1989-06-15 | 1997-02-25 | The Regents Of The University Of Michigan | Methods, compositions and devices for growing human hematopoietic cells |
| US5464764A (en) * | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US6010696A (en) * | 1990-11-16 | 2000-01-04 | Osiris Therapeutics, Inc. | Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells |
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5197985A (en) * | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
| US5733542A (en) * | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
| UA40613C2 (ru) * | 1993-03-31 | 2001-08-15 | Про-Нейрон, Інк. | Полипептид, имеющий активность ингибитора пролиферации стволовых клеток (варианты), фармацевтическая композиция (варианты), фармацевтическая композиция для ингибирования деления стволовых клеток у млекопитающих, фармацевтическая композиция для лечения заболеваний, которые включают гиперпролиферативные состояния, фармацевтическая композиция для дифференциальной защиты нормальных стволовых клеток, отличающихся от лейкозных, способ очистки полипептида |
| US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| US5591625A (en) * | 1993-11-24 | 1997-01-07 | Case Western Reserve University | Transduced mesenchymal stem cells |
| US6288030B1 (en) * | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
| US6174333B1 (en) * | 1994-06-06 | 2001-01-16 | Osiris Therapeutics, Inc. | Biomatrix for soft tissue regeneration using mesenchymal stem cells |
| CA2192103C (en) * | 1994-06-06 | 2002-02-05 | Arnold I. Caplan | Biomatrix for tissue regeneration |
| US6103522A (en) * | 1994-07-20 | 2000-08-15 | Fred Hutchinson Cancer Research Center | Human marrow stromal cell lines which sustain hematopoiesis |
| US5874301A (en) * | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5736396A (en) * | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| US5695998A (en) * | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
| US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
| US5716616A (en) * | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
| US5733541A (en) * | 1995-04-21 | 1998-03-31 | The Regent Of The University Of Michigan | Hematopoietic cells: compositions and methods |
| US5925567A (en) * | 1995-05-19 | 1999-07-20 | T. Breeders, Inc. | Selective expansion of target cell populations |
| US5877299A (en) * | 1995-06-16 | 1999-03-02 | Stemcell Technologies Inc. | Methods for preparing enriched human hematopoietic cell preparations |
| US5858782A (en) * | 1995-11-13 | 1999-01-12 | Regents Of The University Of Michigan | Functional human hematopoietic cells |
| EP0861894B1 (en) * | 1995-11-17 | 2006-03-08 | Asahi Kasei Kabushiki Kaisha | Differentiation-suppressive polypeptide |
| US5716794A (en) * | 1996-03-29 | 1998-02-10 | Xybernaut Corporation | Celiac antigen |
| WO1997040137A1 (en) * | 1996-04-19 | 1997-10-30 | Osiris Therapeutics, Inc. | Regeneration and augmentation of bone using mesenchymal stem cells |
| US5919176A (en) * | 1996-05-14 | 1999-07-06 | Children's Hospital Medical Center Of Northern California | Apparatus and method for collecting blood from an umbilical cord |
| US5827740A (en) * | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| US5916202A (en) * | 1996-08-30 | 1999-06-29 | Haswell; John N. | Umbilical cord blood collection |
| US6335195B1 (en) * | 1997-01-28 | 2002-01-01 | Maret Corporation | Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation |
| US5879318A (en) * | 1997-08-18 | 1999-03-09 | Npbi International B.V. | Method of and closed system for collecting and processing umbilical cord blood |
| WO1999011287A1 (en) * | 1997-09-04 | 1999-03-11 | Osiris Therapeutics, Inc. | Ligands that modulate differentiation of mesenchymal stem cells |
| ES2237089T3 (es) * | 1998-03-13 | 2005-07-16 | Osiris Therapeutics, Inc. | Usos para celulas madre mesenquimatosas humanas no autologas. |
| JP4526186B2 (ja) * | 1998-06-08 | 2010-08-18 | オシリス セラピューティクス，インコーポレイテッド | 造血幹細胞を試験管内で維持する方法と組成物 |
| US6184035B1 (en) * | 1998-11-18 | 2001-02-06 | California Institute Of Technology | Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells |
| JP3089299B2 (ja) * | 1998-12-14 | 2000-09-18 | 京都大学長 | 生体内に毛細血管が豊富な組織を作成するのに用いる新生血管床形成用用具 |
| WO2000046349A1 (en) * | 1999-02-04 | 2000-08-10 | Technion Research & Development Foundation Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
| FR2792202B1 (fr) * | 1999-04-19 | 2003-06-13 | Pharmascience Lab | Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait |
| US8075881B2 (en) * | 1999-08-05 | 2011-12-13 | Regents Of The University Of Minnesota | Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure |
| US6685936B2 (en) * | 1999-10-12 | 2004-02-03 | Osiris Therapeutics, Inc. | Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| EP2206772A3 (en) * | 2000-12-06 | 2010-08-04 | Robert J. Hariri | Method of collecting placental stem cells |
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| EP2336299A1 (en) * | 2001-02-14 | 2011-06-22 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| ES2559031T3 (es) * | 2001-02-14 | 2016-02-10 | Anthrogenesis Corporation | Renovación y repoblación de tejidos descelularizados y órganos cadavéricos por células madre |
| CA2396536A1 (en) * | 2001-08-10 | 2003-02-10 | Saiko Uchida | Human stem cells originated from human amniotic mesenchymal cell layer |
| AU2003205266A1 (en) * | 2002-01-22 | 2003-09-02 | Advanced Cell Technology, Inc. | Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis |
| KR20110036114A (ko) | 2002-02-13 | 2011-04-06 | 안트로제네시스 코포레이션 | 산후 포유류 태반으로부터 유래한 배아-유사 줄기 세포와 그 세포를 사용한 용도 및 치료방법 |
| GB0205867D0 (en) * | 2002-03-13 | 2002-04-24 | Univ Nottingham | Polymer composite loaded with functioning matter |
| US20030187515A1 (en) * | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| MXPA04011851A (es) * | 2002-05-30 | 2005-03-31 | Celgene Corp | Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos. |
| US7422736B2 (en) * | 2002-07-26 | 2008-09-09 | Food Industry Research And Development Institute | Somatic pluripotent cells |
| JP4480128B2 (ja) * | 2002-11-20 | 2010-06-16 | 独立行政法人科学技術振興機構 | マトリックスメタロプロテアーゼ−９の産生を阻害するための薬剤 |
| BRPI0407427A (pt) * | 2003-02-13 | 2006-01-24 | Anthrogenesis Corp | Método para tratar um paciente e para tratar a mielodisplasia |
| PL2322599T3 (pl) * | 2003-06-27 | 2015-10-30 | Depuy Synthes Products Inc | Komórki pozyskiwane poporodowo z tkanki sznura pępowinowego i sposoby pozyskiwania i zastosowania tych komórek do naprawy i regeneracji tkanek miękkich |
| US20050042595A1 (en) * | 2003-08-14 | 2005-02-24 | Martin Haas | Banking of multipotent amniotic fetal stem cells |
| AR046123A1 (es) * | 2003-10-17 | 2005-11-23 | Crc For Innovative Dairy Produ | Aislamiento de celulas simil-celulas madre, uso de las mismas |
| CA2550727A1 (en) * | 2003-12-29 | 2005-07-14 | Centelion | Treatment of coronary or peripheral ischemia |
| KR20070037444A (ko) * | 2004-06-15 | 2007-04-04 | 백스터 인터내셔널 인코포레이티드 | 고체 미립자성 치료제의 생체외 적용방법 |
| US7147626B2 (en) * | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| US7909806B2 (en) * | 2004-09-23 | 2011-03-22 | Anthrogenesis Corporation | Cord blood and placenta collection kit |
| US8017395B2 (en) * | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
| AU2006203990B2 (en) * | 2005-01-07 | 2011-08-11 | Wake Forest University Health Sciences | Regeneration of pancreatic islets by amniotic fluid stem cell therapy |
| US7642091B2 (en) * | 2005-02-24 | 2010-01-05 | Jau-Nan Lee | Human trophoblast stem cells and use thereof |
| US20060222634A1 (en) * | 2005-03-31 | 2006-10-05 | Clarke Diana L | Amnion-derived cell compositions, methods of making and uses thereof |
| DK1869165T3 (en) * | 2005-04-12 | 2016-02-01 | Mesoblast Inc | Isolation of Adult Multipotent Cells by Tissue-Specific Alkaline Phosphate |
| JP2008543783A (ja) * | 2005-06-10 | 2008-12-04 | セルジーン・コーポレーション | ヒト胎盤のコラーゲン組成物、これらの調製方法、これらの使用方法及び組成物を含むキット。 |
| WO2007005807A2 (en) * | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
| US7928280B2 (en) * | 2005-07-13 | 2011-04-19 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| EP1919365A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Ocular plug formed from placenta derived collagen biofabric |
| WO2007011693A2 (en) * | 2005-07-14 | 2007-01-25 | Medistem Laboratories, Inc. | Compositions of placentally-derived stem cells for the treatment of cancer |
| AU2006304277B2 (en) * | 2005-10-13 | 2012-07-05 | Celularity Inc. | Immunomodulation using placental stem cells |
| ES2628129T3 (es) * | 2005-12-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Tratamiento de la enfermedad vascular periférica utilizando células derivadas del posparto |
| ES2671355T3 (es) * | 2005-12-29 | 2018-06-06 | Anthrogenesis Corporation | Poblaciones de células madre placentarias |
| WO2007146105A2 (en) * | 2006-06-05 | 2007-12-21 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
| US20080050814A1 (en) * | 2006-06-05 | 2008-02-28 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
| EP2035552A2 (en) * | 2006-06-09 | 2009-03-18 | Anthrogenesis Corporation | Placental niche and use thereof to culture stem cells |
| US20090081171A1 (en) * | 2006-08-11 | 2009-03-26 | Yu-Show Fu | Cell system for alleviating syndromes of Parkinson's disease in a mammal |
| WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
| US20080050347A1 (en) * | 2006-08-23 | 2008-02-28 | Ichim Thomas E | Stem cell therapy for cardiac valvular dysfunction |
| NZ595854A (en) * | 2006-10-23 | 2013-04-26 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations (ELOVL2, ST3GAL6, STGALNAC5, SLC12A8) |
| CA2677679A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations |
| US20090053182A1 (en) * | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
| US20090016999A1 (en) * | 2007-07-13 | 2009-01-15 | Michael Cohen | Embryonic cell compositions for wound treatment |
| MX2008005751A (es) * | 2007-09-13 | 2009-04-16 | Clifford L Librach | Metodo de aislamiento y uso de celulas derivadas del tejido del cordon umbilical del primer trimestre. |
| KR101738285B1 (ko) * | 2007-09-19 | 2017-05-29 | 플루리스템 리미티드 | 태반 조직 유래의 부착세포를 유효성분으로 포함하는 허혈 치료용 약학적 조성물 |
| KR20210118946A (ko) * | 2007-09-26 | 2021-10-01 | 안트로제네시스 코포레이션 | 인간 태반 관류액으로부터의 혈관형성 세포 |
| KR20180108887A (ko) * | 2008-08-20 | 2018-10-04 | 안트로제네시스 코포레이션 | 단리된 태반 세포를 사용한 뇌졸중 치료 |
| KR20220025141A (ko) * | 2008-08-20 | 2022-03-03 | 셀룰래리티 인코포레이티드 | 개선된 세포 조성물 및 그의 제조 방법 |
| WO2010021756A1 (en) * | 2008-08-22 | 2010-02-25 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
| CN201299504Y (zh) * | 2008-11-11 | 2009-09-02 | 薛华 | 一种方便搭挂的毛巾 |
| WO2011002959A1 (en) * | 2009-07-02 | 2011-01-06 | Anthrogenesis Corporation | Method of producing erythrocytes without feeder cells |
| TWI395125B (zh) * | 2009-07-14 | 2013-05-01 | Sonix Technology Co Ltd | 電容式觸控感應電路 |
-
2008
- 2008-09-26 KR KR1020217028887A patent/KR20210118946A/ko not_active Ceased
- 2008-09-26 AU AU2008305516A patent/AU2008305516A1/en not_active Abandoned
- 2008-09-26 BR BRPI0818191A patent/BRPI0818191A8/pt not_active Application Discontinuation
- 2008-09-26 KR KR1020207033934A patent/KR20200136051A/ko not_active Withdrawn
- 2008-09-26 KR KR1020187015067A patent/KR20180059583A/ko not_active Ceased
- 2008-09-26 US US12/239,679 patent/US20090104164A1/en not_active Abandoned
- 2008-09-26 MX MX2010003217A patent/MX2010003217A/es not_active Application Discontinuation
- 2008-09-26 EP EP08833350A patent/EP2205719A1/en not_active Withdrawn
- 2008-09-26 CA CA2700613A patent/CA2700613C/en active Active
- 2008-09-26 KR KR1020207011050A patent/KR20200043517A/ko not_active Withdrawn
- 2008-09-26 CN CN2008801178057A patent/CN101978045A/zh active Pending
- 2008-09-26 WO PCT/US2008/011167 patent/WO2009042201A1/en active Application Filing
- 2008-09-26 RU RU2010116271/10A patent/RU2010116271A/ru not_active Application Discontinuation
- 2008-09-26 KR KR1020107008970A patent/KR101644659B1/ko not_active Expired - Fee Related
- 2008-09-26 KR KR1020227028466A patent/KR20220122774A/ko not_active Ceased
- 2008-09-26 KR KR1020197012717A patent/KR20190050867A/ko not_active Ceased
- 2008-09-26 KR KR1020157020016A patent/KR101645311B1/ko not_active Expired - Fee Related
- 2008-09-26 JP JP2010526961A patent/JP5703493B2/ja not_active Expired - Fee Related
- 2008-09-26 KR KR1020167020487A patent/KR20160092062A/ko not_active Ceased
-
2010
- 2010-03-25 IL IL204762A patent/IL204762A0/en active IP Right Grant
-
2014
- 2014-09-26 JP JP2014196899A patent/JP5985569B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-17 IL IL242645A patent/IL242645B/en active IP Right Grant
- 2015-11-17 IL IL242644A patent/IL242644B/en active IP Right Grant
-
2016
- 2016-08-03 JP JP2016152885A patent/JP2017002071A/ja active Pending
-
2018
- 2018-06-26 IL IL260292A patent/IL260292A/en unknown
- 2018-07-06 JP JP2018129253A patent/JP2018172425A/ja active Pending
-
2020
- 2020-08-13 JP JP2020136719A patent/JP2020189872A/ja active Pending
-
2022
- 2022-08-19 JP JP2022131194A patent/JP2022166249A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010116271A (ru) | Ангиогенные клетки из плацентарного перфузата человека | |
| JP2010540530A5 (ru) | ||
| Park et al. | Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction | |
| Ishida et al. | Transplantation of human-induced pluripotent stem cell-derived cardiomyocytes is superior to somatic stem cell therapy for restoring cardiac function and oxygen consumption in a porcine model of myocardial infarction | |
| Lajiness et al. | Origin, development, and differentiation of cardiac fibroblasts | |
| Shadrin et al. | Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues | |
| Gao et al. | Large cardiac muscle patches engineered from human induced-pluripotent stem cell–derived cardiac cells improve recovery from myocardial infarction in swine | |
| Leri et al. | Myocardial regeneration and stem cell repair | |
| Mirotsou et al. | Paracrine mechanisms of stem cell reparative and regenerative actions in the heart | |
| Chacko et al. | Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells | |
| Yang et al. | VEGF enhances functional improvement of postinfarcted hearts by transplantation of ESC-differentiated cells | |
| Lux et al. | In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic mechanical stimulation | |
| Zhang et al. | Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy | |
| Xiong et al. | Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells | |
| Castro et al. | Cellular and molecular heterogeneity associated with vessel formation processes | |
| WO2006121532A3 (en) | Treatment for heart disease | |
| Fujita et al. | Myocardial cell sheet therapy and cardiac function | |
| Taylor | Cell-based myocardial repair: how should we proceed? | |
| Mayfield et al. | Resident cardiac stem cells and their role in stem cell therapies for myocardial repair | |
| Lilyanna et al. | Cord lining-mesenchymal stem cells graft supplemented with an omental flap induces myocardial revascularization and ameliorates cardiac dysfunction in a rat model of chronic ischemic heart failure | |
| Dimarakis et al. | Adult bone marrow-derived stem cells and the injured heart: just the beginning? | |
| Costa et al. | Optical mapping of cryoinjured rat myocardium grafted with mesenchymal stem cells | |
| Dall et al. | Oxygen cycling to improve survival of stem cells for myocardial repair: A review | |
| Vu et al. | Myocardial restoration: is it the cell or the architecture or both? | |
| Pijnappels et al. | The integrative aspects of cardiac physiology and their implications for cell‐based therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20121126 |